Erika P. Hamilton, MD, on Treating Breast Cancer With CDK4/6 Inhibitors: Expert Perspective

Posted: Sunday, September 20, 2020

Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses the emergence of CDK4/6 inhibitors, how they have transformed the treatment of advanced hormone receptor–positive breast cancers, and what practitioners need to know in order to select the right agent for the right patient.